论文部分内容阅读
目的探讨孟鲁司特联合布地奈德治疗儿童咳嗽变异性哮喘的临床疗效及安全性。方法选取符合标准的患儿40例,给予布地奈德气雾剂吸入和孟鲁司特钠咀嚼片口服,疗程3个月。结果患儿咳嗽缓解时间为(5.67±1.83)d,咳嗽消失时间为(10.63±3.64)d;治疗前FEV1为(54.69±3.90)%,治疗后提高至(72.54±2.84)%,差异存在统计学意义(P<0.05)。总有效率为95.00%,治疗过程中均未发生明显药物不良反应。结论孟鲁司特联合布地奈德治疗儿童咳嗽变异性哮喘,有效缓解患儿的临床症状,副作用少,依从性好,并能降低糖皮质激素的用量。
Objective To investigate the clinical efficacy and safety of montelukast combined with budesonide in the treatment of children with cough variant asthma. Methods Forty children with standard criteria were enrolled and given budesonide aerosol inhalation and montelukast sodium chewable tablet orally for 3 months. Results The cough relief time was (5.67 ± 1.83) d and the disappearance time of cough was (10.63 ± 3.64) days. The FEV1 was (54.69 ± 3.90)% before treatment and increased to (72.54 ± 2.84)% after treatment, Significance (P <0.05). The total effective rate was 95.00%. No significant adverse drug reactions occurred during the course of treatment. Conclusion Montelukast combined with budesonide in children with cough variant asthma, effective in relieving children’s clinical symptoms, fewer side effects, good compliance, and can reduce the amount of glucocorticoid.